EU GMP: Guidelines for Good Manufacturing Practices

Author: Maren Fichtner | August 27, 2026

Definition: What is EU GMP?

EU GMP (Good Manufacturing Practice) is the European guideline on good manufacturing practice for medicinal products, published as EudraLex Volume 4. It defines fundamental requirements for personnel, facilities, processes, documentation, and quality control in the manufacture of medicinal products and is a mandatory prerequisite for the granting of a manufacturing authorization in the European Union.

Publisher: European Commission

Reference: EudraLex Volume 4

Who is subject to EU GMP?

This guidance applies to all manufacturers of medicinal products, active pharmaceutical ingredients, and certain investigational medicinal products that manufacture in the EU or supply the EU market—from large pharmaceutical companies to contract manufacturers and suppliers of starting materials—provided they carry out GMP-related activities.

Overview of Core Requirements

Pharmaceutical Quality System: A Framework of Responsibilities, Processes, and Continuous Improvement
Personnel and Training: Sufficiently qualified personnel with documented expertise
Facilities and Equipment: Suitable, validated production and storage areas
Documentation: Complete , traceable records of all manufacturing-related steps
Production and Quality Control: Validated processes with defined testing and release steps
Annexes for Special Areas: Supplementary requirements, such as for sterile production (Annex 1) or computerized systems (Annex 11)

Difference from FDA cGMP

EU GMP and FDA cGMP pursue the same fundamental goal—consistent, quality-assured pharmaceutical manufacturing—and are largely identical in content, as both are based on common international principles such as the ICH guidelines. The main difference lies in their legal basis and structure: EU GMP is organized into parts and annexes in EudraLex Volume 4 and is directly applicable in EU member states, while FDA cGMP is codified in 21 CFR Parts 210 and 211 and applies to the U.S. market. Through mutual recognition agreements such as the EU-U.S. Mutual Recognition Agreement, GMP inspections are increasingly recognized on a reciprocal basis, which reduces the burden of duplicate efforts for manufacturers operating internationally.

Consequences of Noncompliance

Without compliance with EU GMP, a manufacturing authorization will not be granted; furthermore, an existing authorization may be revoked in the event of serious deficiencies. Production must then be suspended. During GMP inspections, documentation-related deficiencies regularly result in notices of nonconformity. In the event of repeated violations, batch holds, product recalls, and the loss of market authorization for the affected products may result.

Frequently Asked Questions About EU GMP

Is EU GMP required by law?

Yes, it is mandatory under Directive 2001/83/EC and national pharmaceutical laws; it is a prerequisite for obtaining a manufacturing license.

How is the guide organized?

In Part I (Medicines), Part II (Active Ingredients), Part III (GMP Documents), and numerous annexes for specialized areas.

What is the difference from FDA cGMP?

Substantively very similar, but with different legal bases; recognition agreements reduce duplicate efforts.

Who monitors compliance?

The national drug regulatory authorities of the EU member states, coordinated by the EMA.

Successfully Implementing EU GMP

The greatest operational burden lies in maintaining complete documentation across all areas covered by the guidelines—from batch records to cleaning records to deviation management—that is ready for inspection at any time. Connected worker platforms such as weasl address these requirements as an automatic byproduct of daily production and provide complete, tamper-proof records for every GMP inspection.

Learn more about weasl and download our product flyer now.

EU GMP